Otsuka Bolsters Oncology Portfolio With Acquisition Of PDL’s Busulfex
This article was originally published in The Pink Sheet Daily
Executive Summary
Otsuka acquires first-in-class oncology product with over $29 million in sales for year ended Sept. 30.